Table 2 Tumor characteristics
From: Weight changes according to treatment in a diverse cohort of breast cancer patients
Tumor Characteristics, N (%) | All | NHPI | Asian | White | Other/Unknown |
|---|---|---|---|---|---|
Stage | |||||
In situ | 61 (15.7) | 15 (12.7) | 25 (18.9) | 18 (14) | 3 (30) |
Localized | 241 (62) | 70 (59.3) | 80 (60.6) | 87 (67.4) | 4 (40) |
Regional | 87 (22.4) | 33 (28) | 27 (20.5) | 24 (18.6) | 3 (30) |
Tumor size, mm, mean (SD) | 18.7 (14.5) | 19.1 (16.8) | 18.9 (15.4) | 17.7 (11.3) | 24.7 (11.9) |
Grade | |||||
Well differentiated | 78 (20.1) | 25 (21.2) | 25 (18.9) | 28 (21.7) | 0 |
Moderately differentiated | 183 (47) | 58 (49.2) | 67 (50.8) | 55 (42.6) | 3 (30) |
Poorly differentiated | 90 (23.1) | 25 (21.2) | 28 (21.2) | 34 (26.4) | 3 (30) |
Undifferentiated | 12 (3.1) | 5 (4.2) | 3 (2.3) | 4 (3.1) | 0 |
Unknown | 26 (6.7) | 5 (4.2) | 9 (6.8) | 8 (6.2) | 4 (40) |
Lymph node | |||||
Positive | 77 (19.8) | 31 (26.3) | 22 (16.7) | 21 (16.3) | 3 (30) |
Negative | 309 (79.4) | 87 (73.7) | 107 (81.1) | 108 (83.7) | 7 (70) |
Unknown | 3 (0.8) | 0 | 3 (2.3) | 0 | 0 |
Estrogen receptor status | |||||
Positive | 327 (84) | 102 (86.4) | 108 (81.8) | 109 (84.5) | 8 (80) |
Negative | 52 (13.4) | 13 (11) | 19 (14.4) | 18 (14) | 2 (20) |
Borderline | 1 (0.3) | 1 (0.9) | 0 (0) | 0 (0) | 0 (0) |
Unknown | 9 (2.3) | 2 (1.7) | 5 (3.8) | 2 (1.6) | 0 (0) |
Progesterone receptor status | |||||
Positive | 288 (74) | 93 (78.8) | 94 (71.1) | 94 (72.9) | 7 (70) |
Negative | 89 (22.9) | 23 (19.5) | 31 (23.5) | 32 (24.8) | 3 (30) |
Borderline | 2 (0.5) | 0 (0) | 1 (0.8) | 1 (0.8) | 0 (0) |
Unknown | 10 (2.6) | 2 (1.7) | 6 (4.6) | 2 (1.6) | 0 (0) |
Her2 status | |||||
Positive | 20 (5.1) | 3 (2.5) | 10 (7.6) | 6 (4.7) | 1 (10) |
Negative | 210 (54) | 66 (55.9) | 62 (47) | 77 (59.7) | 5 (50) |
Borderline | 2 (0.5) | 0 | 0 | 2 (1.6) | 0 (0) |
Unknown | 157 (40.4) | 49 (41.5) | 60 (45.5) | 44 (34.1) | 4 (40) |